Central Pacific Bank Trust Division Lowers Stake in Hologic, Inc. (NASDAQ:HOLX)

Central Pacific Bank Trust Division decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 34.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 558 shares of the medical equipment provider’s stock after selling 296 shares during the period. Central Pacific Bank Trust Division’s holdings in Hologic were worth $40,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Wolff Wiese Magana LLC acquired a new position in Hologic in the 3rd quarter valued at $25,000. General Partner Inc. acquired a new position in Hologic in the fourth quarter valued at $26,000. First Horizon Advisors Inc. lifted its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the period. Sunbelt Securities Inc. purchased a new position in Hologic during the second quarter worth about $37,000. Finally, Cromwell Holdings LLC boosted its stake in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 416 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 2.0 %

NASDAQ HOLX opened at $73.19 on Monday. The company’s fifty day simple moving average is $76.72 and its 200-day simple moving average is $78.54. The stock has a market cap of $16.61 billion, a P/E ratio of 21.98, a PEG ratio of 2.32 and a beta of 0.97. Hologic, Inc. has a 52 week low of $70.36 and a 52 week high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the prior year, the company posted $0.89 EPS. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. Equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.75% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HOLX. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Jefferies Financial Group initiated coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. UBS Group lifted their price target on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Raymond James increased their target price on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. boosted their price target on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $89.50.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.